Background & Aims: The efficacy of currently available therapeutic: agents for cholestatic pruritus is often disappointing. The aim of this study was to assess the antipruritic effect of naltrexone, an oral opiate receptor antagonist. Methods: Sixteen patients with pruritus of chronic cholestasis were randomized to receive naltrexone (4-week course of 50 mg naltrexone daily) or placebo, Pruritus, duality of sleep, fatigue (using visual analogue scales), side effects, and liver function were assessed every 2 weeks. Serum naltrexone and 6 beta-naltrexol concentrations in all patients and 5 healthy controls were measured during the first day of naltrexone treatment. Results: Mean changes with respect to baseline were significantly different, in favor of the naltrexone group, for daytime itching (-54% vs, 8%; P < 0.001) and nighttime itching (-44% vs. 7%, P = 0.003). In 4 naltrexone-treated patients, side effects (transient in 3 cases) consistent with an opiate withdrawal syndrome were noted. No deterioration of the underlying disease was observed. Naltrexone and 6 beta-naltrexol levels did not differ between patients and controls, and there was no significant association with treatment response. Conclusions: For patients with cholestatic liver disease and itching, refractory to regular antipruritic therapy, oval naltrexone may be an effective and well-tolerated alternative.

Oral naltrexone treatment for cholestatic pruritus: a double-blind, placebo-controlled study / F. H. J., Wolfhagen; E., Sternieri; W. C. J., Hop; Vitale, Giovanni; Bertolotti, Marco; H. R., van Buuren. - In: GASTROENTEROLOGY. - ISSN 0016-5085. - 113(4)(1997), pp. 1264-1269.

Oral naltrexone treatment for cholestatic pruritus: a double-blind, placebo-controlled study

VITALE, Giovanni;BERTOLOTTI, Marco;
1997

Abstract

Background & Aims: The efficacy of currently available therapeutic: agents for cholestatic pruritus is often disappointing. The aim of this study was to assess the antipruritic effect of naltrexone, an oral opiate receptor antagonist. Methods: Sixteen patients with pruritus of chronic cholestasis were randomized to receive naltrexone (4-week course of 50 mg naltrexone daily) or placebo, Pruritus, duality of sleep, fatigue (using visual analogue scales), side effects, and liver function were assessed every 2 weeks. Serum naltrexone and 6 beta-naltrexol concentrations in all patients and 5 healthy controls were measured during the first day of naltrexone treatment. Results: Mean changes with respect to baseline were significantly different, in favor of the naltrexone group, for daytime itching (-54% vs, 8%; P < 0.001) and nighttime itching (-44% vs. 7%, P = 0.003). In 4 naltrexone-treated patients, side effects (transient in 3 cases) consistent with an opiate withdrawal syndrome were noted. No deterioration of the underlying disease was observed. Naltrexone and 6 beta-naltrexol levels did not differ between patients and controls, and there was no significant association with treatment response. Conclusions: For patients with cholestatic liver disease and itching, refractory to regular antipruritic therapy, oval naltrexone may be an effective and well-tolerated alternative.
113(4)
1264
1269
Oral naltrexone treatment for cholestatic pruritus: a double-blind, placebo-controlled study / F. H. J., Wolfhagen; E., Sternieri; W. C. J., Hop; Vitale, Giovanni; Bertolotti, Marco; H. R., van Buuren. - In: GASTROENTEROLOGY. - ISSN 0016-5085. - 113(4)(1997), pp. 1264-1269.
F. H. J., Wolfhagen; E., Sternieri; W. C. J., Hop; Vitale, Giovanni; Bertolotti, Marco; H. R., van Buuren
File in questo prodotto:
Non ci sono file associati a questo prodotto.
Pubblicazioni consigliate

Caricamento pubblicazioni consigliate

Licenza Creative Commons
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/11380/310441
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 275
  • ???jsp.display-item.citation.isi??? 220
social impact